Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) EBIT (2016 - 2025)

Historic EBIT for Outlook Therapeutics (OTLK) over the last 7 years, with Q4 2025 value amounting to -$13.5 million.

  • Outlook Therapeutics' EBIT changed N/A to -$13.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$58.9 million, marking a year-over-year change of. This contributed to the annual value of -$67.1 million for FY2025, which is 647.33% up from last year.
  • Latest data reveals that Outlook Therapeutics reported EBIT of -$13.5 million as of Q4 2025.
  • Outlook Therapeutics' EBIT's 5-year high stood at -$12.4 million during Q1 2025, with a 5-year trough of -$17.3 million in Q3 2025.